Of 7119 melanomas with prior hybrid capture-based DNA sequencing, 37 distinct cases (0.5%) featured small in-frame deletions that resulted in known or likely activation of MAP2K1. Among patients with MAP2K1 in-frame deleted melanomas, the ages ranged from 28 to 89 years, with a median of 66 years. This evidence concerns the gene MAP2K1 and melanoma.